Treatment of BV With First Deqularum and Then Direkt After Clindamycin (BV)
Treatment of BV With First Deqularum and Then Direkt After With Vaginal Clindamycin Cream.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The hypoteses is that deqularum cloride takes away the biofilm so that clindamycin will kills the bacteria.
Cure rate will be followed up after 1 month and then after 6 month
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: P-G Larsson
- Phone Number: +46500431000
- Email: p-g.larsson@vgregion.se
Study Locations
-
-
-
Skövde, Sweden, 541 85
- Recruiting
- Department of Ob/Gyn, Skaraborgshospital Skövde
-
Contact:
- Per-Göran B Larsson, professor
- Phone Number: +46500431000
- Email: p-g.larsson@vgregion.se
-
Contact:
- Karin Breding, dr
- Phone Number: +46500431000
- Email: karin.breding@vgregion.se
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy women with BV
Exclusion Criteria:
- women treated with antibiotics within 1 month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: treatment of BV
all patients be treated with first Deqularum then with clindamycin Cream,
|
All patients will get the same treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cure of BV
Time Frame: 6 month
|
cure rate of BV
|
6 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: P-G Larsson, Professor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12 (Israel lung Association)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.